Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

GAITHERSBURG, Md., Jan. 3, 2024 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42th Annual J.P. Morgan Healthcare Conference.

Recordings
A replay of the recorded presentation and Q&A will be available through the Events & presentations page of the Company’s website at ir.novavax.com for 30 days from the date of the conference.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax’s patented Matrix-M adjuvant to enhance the immune response. Focused on the world’s most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.

Contacts:
Investors
Erika Schultz
240-268-2022
[email protected] 

Media
Ali Chartan
240-720-7804
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-the-42nd-annual-jp-morgan-healthcare-conference-302024821.html

SOURCE NOVAVAX, INC